|
FGFR1 wild-type
|
lung cancer
|
decreased response
|
Fexagratinib
|
Preclinical |
Actionable |
In a preclinical study, FGFR1 non-amplified lung cancer cell lines demonstrated reduced sensitivity to AZD4547 induced growth inhibition in culture and in xenograft models (PMID: 23082000).
|
23082000
|
|
FGFR1 wild-type
|
breast cancer
|
resistant
|
Ponatinib
|
Preclinical |
Actionable |
In a preclinical study, ER-positive breast cancer cells with wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).
|
22238366
|
|
FGFR1 amp
|
lung cancer
|
sensitive
|
Fexagratinib
|
Preclinical |
Actionable |
In a preclinical study, AZD4547 inhibited proliferation of lung cancer cell lines harboring FGFR1 amplification in culture and induced tumor regression in xenograft models (PMID: 23082000).
|
23082000
|
|
FGFR1 amp
|
breast cancer
|
no benefit
|
Fexagratinib
|
Phase II |
Actionable |
In a Phase II clinical trial, treatment with AZD4547 resulted in a response rate of 12.5% (1/8) in patients with FGFR1-amplified breast cancer, and did not meet the predetermined criteria for efficacy (PMID: 27179038).
|
27179038
|
|
FGFR1 amp
|
lung squamous cell carcinoma
|
no benefit
|
Fexagratinib
|
Phase I |
Actionable |
In a Phase Ib trial, AZD4547 demonstrated limited efficacy in patients with squamous cell lung cancer with FGFR1 amplification, resulting in an overall response rate of 8% (1/15) and a median overall survival of 4.9 months (PMID: 28615371; NCT00979134).
|
28615371
|
|
FGFR1 amp
|
lung non-small cell carcinoma
|
sensitive
|
Fexagratinib
|
Preclinical - Pdx |
Actionable |
In a preclinical study, AZD4547 inhibited FGFR1 signaling and resulted in tumor regression in patient-derived xenograft models of non-small cell lung carcinoma harboring FGFR1 amplification, wild-type for EGFR, K-Ras and negative for EML4-ALK fusion (PMID: 23082000).
|
23082000
|
|
FGFR1 amp
|
lung large cell carcinoma
|
sensitive
|
Fexagratinib
|
Preclinical |
Actionable |
In a preclinical study, AZD4547 inhibited proliferation of a large cell lung cancer cell line harboring FGFR1 amplification in culture and induced tumor regression in xenograft models (PMID: 23082000).
|
23082000
|
|
FGFR1 amp
|
lung small cell carcinoma
|
sensitive
|
Fexagratinib
|
Preclinical |
Actionable |
In a preclinical study, AZD4547 inhibited proliferation of a small cell lung cancer cell line harboring FGFR1 amplification in culture (PMID: 23082000).
|
23082000
|
|
FGFR1 amp
|
synovial sarcoma
|
sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, AZD4547 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980).
|
27535980
|
|
FGFR1 amp
|
Advanced Solid Tumor
|
unknown
|
Fexagratinib
|
Phase II |
Actionable |
In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 7 of 17 patients with advanced solid tumors harboring FGFR1 amplification, with 6 of the 17 patients experiencing progressive disease and 4 not evaluable for response, and a 6-month progression-free survival rate of 0% (PMID: 32463741; NCT02465060).
|
32463741
|
|
FGFR1 amp
|
head and neck carcinoma
|
predicted - sensitive
|
Infigratinib
|
Case Reports/Case Series |
Actionable |
In a Phase I trial, a patient with head and neck carcinoma harboring an FGFR1 amplification demonstrated a reduction in tumor size when treated with Truseltiq (infigratinib) (PMID: 27870574).
|
27870574
|
|
FGFR1 amp
|
breast cancer
|
sensitive
|
Infigratinib
|
Phase I |
Actionable |
In a Phase I trial, 28% (9/32) of breast cancer patients harboring FGFR1 amplification demonstrated stable disease when treated with Truseltiq (infigratinib) (PMID: 27870574).
|
27870574
|
|
FGFR1 amp
|
lung squamous cell carcinoma
|
sensitive
|
Infigratinib
|
Phase I |
Actionable |
In a Phase I trial, patients with lung squamous cell carcinoma harboring an FGFR1 amplification demonstrated a disease control rate of 50% (18/36) when treated with Truseltiq (infigratinib), resulting in 14 patients with stable disease and 4 patients with a partial response (PMID: 27870574).
|
27870574
|
|
FGFR1 amp
|
lung non-small cell carcinoma
|
sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Truseltiq (infigratinib) inhibited Erk signaling and growth of FGFR1-amplified non-small cell lung carcinoma cells in culture (PMID: 28630215).
|
28630215
|
|
FGFR1 amp
|
synovial sarcoma
|
sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Truseltiq (infigratinib) inhibited survival of FGFR1-amplified synovial sarcoma cells in culture (PMID: 27535980).
|
27535980
|
|
FGFR1 amp
|
estrogen-receptor positive breast cancer
|
resistant
|
Alpelisib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring an FGFR1 amplification demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27126994).
|
27126994
|
|
FGFR1 amp
|
lung squamous cell carcinoma
|
no benefit
|
Dovitinib
|
Phase II |
Actionable |
In a Phase II clinical trial, dovitinib treatment resulted in a objective response rate of 11.5% (3/26, all partial responses) and disease control rate of 50% (13/26), and a median progression-free survival of 2.9 months in lung squamous cell carcinoma patients with FGFR1 amplification, and FGFR1 amplification was not determined to be a predictive biomarker for sensitivity (PMID: 27315356).
|
27315356
|
|
FGFR1 amp
|
estrogen-receptor positive breast cancer
|
sensitive
|
Dovitinib
|
Preclinical |
Actionable |
In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in estrogen receptor (ER)-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366).
|
22238366
|
|
FGFR1 amp
|
Her2-receptor positive breast cancer
|
sensitive
|
Dovitinib
|
Phase II |
Actionable |
In a Phase II trial, Dovitinib (TKI258) promoted 6-month stable disease in Erbb2 (Her2)-positive breast cancer patients with FGFR1 amplification (PMID: 23658459).
|
23658459
|
|
FGFR1 amp
|
estrogen-receptor positive breast cancer
|
sensitive
|
Nintedanib
|
Preclinical |
Actionable |
In a preclinical study, Ofev (nintedanib) inhibited the growth of ER-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366).
|
22238366
|
|
FGFR1 amp
|
uterine carcinosarcoma
|
predicted - sensitive
|
Pazopanib
|
Case Reports/Case Series |
Actionable |
In a clinical case study, Votrient (pazopanib) treatment resulted in disease control for approximately 7 months in a patient with refractory uterine carcinosarcoma with FGFR1 amplification (PMID: 35586703).
|
35586703
|
|
FGFR1 amp
|
Her2-receptor negative breast cancer
|
predicted - sensitive
|
Pazopanib
|
Case Reports/Case Series |
Actionable |
In a clinical case study, a patient with ERBB2 (HER2)-receptor negative breast cancer harboring FGFR1 amplification demonstrated antitumor activity when treated with Votrient (pazopanib), including a near complete loss of brain lesions and improved function of the liver (PMID: 29223982).
|
29223982
|
|
FGFR1 amp
|
breast cancer
|
sensitive
|
Ponatinib
|
Preclinical |
Actionable |
In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in ER-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366).
|
22238366
|
|
FGFR1 amp
|
Ewing sarcoma
|
predicted - sensitive
|
Ponatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Iclusig (ponatinib) inhibited proliferation of Ewing’s sarcoma cell lines with FGFR1 copy number gain in culture (PMID: 26179511).
|
26179511
|
|
FGFR1 amp
|
lung squamous cell carcinoma
|
sensitive
|
Ponatinib
|
Preclinical |
Actionable |
In a preclinical study, Iclusig (ponatinib) inhibited growth of squamous cell lung cancer cell lines harboring FGFR1 amplification (PMID: 22238366).
|
22238366
|
|
FGFR1 amp
|
lung squamous cell carcinoma
|
no benefit
|
RO4987655
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).
|
26438159
|
|
FGFR1 amp
|
lung non-small cell carcinoma
|
no benefit
|
RO4987655
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).
|
26438159
|
|
FGFR1 amp
|
lung small cell carcinoma
|
no benefit
|
RO4987655
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).
|
26438159
|
|
FGFR1 amp
|
lung squamous cell carcinoma
|
no benefit
|
Selumetinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).
|
26438159
|
|
FGFR1 amp
|
lung non-small cell carcinoma
|
no benefit
|
Selumetinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).
|
26438159
|
|
FGFR1 amp
|
lung small cell carcinoma
|
no benefit
|
Selumetinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).
|
26438159
|
|
FGFR1 amp
|
breast cancer
|
no benefit
|
Sunitinib
|
Phase II |
Actionable |
In a Phase II trial (TAPUR), Sutent (sunitinib) treatment did not meet the predetermined efficacy criteria in metastatic breast cancer patients with FGFR1 amplification (n=26), FGFR1 mutation (n=1), or both (n=3), resulting in disease control in 6 of 27 patients, with 2 partial responses and stable disease of at least 16 weeks in 4 patients, an objective response rate of 7% (2/27), median progression-free survival of 9 weeks, and a median overall survival of 34 weeks (PMID: 38354330; NCT02693535).
|
38354330
|
|
FGFR1 amp
|
lung cancer
|
no benefit
|
Brivanib
|
Preclinical |
Actionable |
In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of lung cancer cells with FGFR1 amplification in culture (PMID: 22238366).
|
22238366
|
|
FGFR1 amp
|
estrogen-receptor positive breast cancer
|
no benefit
|
Brivanib
|
Preclinical |
Actionable |
In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of estrogen receptor (ER)-positive breast cancer cells with FGFR2 amplification in culture (PMID: 22238366).
|
22238366
|
|
FGFR1 amp
|
estrogen-receptor positive breast cancer
|
sensitive
|
Cediranib
|
Preclinical |
Actionable |
In a preclinical study, Cediranib (AZD-2171) inhibited growth of estrogen receptor (ER)-positive breast cancer cells with FGFR1 amplification in culture (PMID: 22238366).
|
22238366
|
|
FGFR1 amp
|
lung squamous cell carcinoma
|
predicted - sensitive
|
Zoligratinib
|
Case Reports/Case Series |
Actionable |
In a Phase I trial, Debio 1347 treatment resulted in a stable disease with 26.7% reduction of tumor size and 100% decrease of DUSP6 score in a patient with lung squamous cell carcinoma harboring FGFR1 amplification (PMID: 30745300; NCT01948297).
|
30745300
|
|
FGFR1 amp
|
lung non-small cell carcinoma
|
sensitive
|
Zoligratinib
|
Preclinical |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of non-small cell lung cancer cell lines harboring FGFR1 amplification in culture (PMID: 25169980).
|
25169980
|
|
FGFR1 amp
|
lung small cell carcinoma
|
sensitive
|
Zoligratinib
|
Preclinical |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of small cell lung cancer cell lines harboring FGFR1 amplification in culture (PMID: 25169980).
|
25169980
|
|
FGFR1 amp
|
Advanced Solid Tumor
|
predicted - sensitive
|
Zoligratinib
|
Phase I |
Actionable |
In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).
|
30745300
|
|
FGFR1 amp
|
lung cancer
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Balversa (erdafitinib) inhibited FGFR downstream signaling and proliferation of several lung cancer cell lines with FGFR1 amplification in culture, and inhibited tumor growth in an FGFR1-amplified lung cancer cell line xenograft model (PMID: 28341788).
|
28341788
|
|
FGFR1 amp
|
Advanced Solid Tumor
|
no benefit
|
Erdafitinib
|
Phase II |
Actionable |
In a Phase II trial (MATCH), Balversa (erdafitinib) treatment resulted in an objective response rate of 0% (0/18), median progression-free survival of 1.7 months, and median overall survival of 4.2 months in patients with advanced solid tumors with FGFR1 (n=12), FGFR2 (n=3), FGFR3 (n=2), or FGFR4 (n=1) amplification (PMID: 38603651; NCT02465060).
|
38603651
|
|
FGFR1 amp
|
lung carcinoma
|
sensitive
|
Lucitanib
|
Preclinical - Cell line xenograft |
Actionable |
in a preclinical study, Lucitanib (E-3810) preferentially inhibited growth of FGFR1-amplified lung carcinoma cell lines in culture and in cell line xenograft models (PMID: 27988457).
|
27988457
|
|
FGFR1 amp
|
estrogen-receptor positive breast cancer
|
sensitive
|
Lucitanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring FGFR1 amplification demonstrated sensitivity to treatment with Lucitanib (E-3810) in culture (PMID: 27126994).
|
27126994
|
|
FGFR1 amp
|
Her2-receptor negative breast cancer
|
predicted - sensitive
|
Lucitanib
|
Phase II |
Actionable |
In a Phase II (FINESSE) trial, Lucitanib (E-3810) treatment resulted in an objective response rate (ORR) of 19% (6/32) and a clinical benefit rate of 41% (13/32) in patients with metastatic hormone receptor-positive, Erbb2 (Her2)-negative breast cancer harboring FGFR1 amplification, ORR was improved (22%, 5/23 vs 9%, 5/53) in patients with high level FGFR1 amplification (FGFR1/centromere ratio>=4) compared to those without (PMID: 31619444; NCT02053636).
|
31619444
|
|
FGFR1 amp
|
triple-receptor negative breast cancer
|
predicted - sensitive
|
Lucitanib
|
Preclinical - Pdx |
Actionable |
In a preclinical study, Lucitanib (E-3810) treatment resulted in reduced tumor volume in FGFR1-amplified triple-negative breast cancer patient-derived xenograft (PDX) models (PMID: 34593528).
|
34593528
|
|
FGFR1 amp
|
lung cancer
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Lytgobi (futibatinib) treatment led to inhibition of cell proliferation in lung cancer cell lines harboring FGFR1 amplification in culture, and led to inhibition of tumor growth in a cell line xenograft model with a daily dosing regimen, but not with an intermittent dosing regimen (PMID: 32973082).
|
32973082
|
|
FGFR1 amp
|
breast cancer
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lytgobi (futibatinib) treatment led to inhibition of cell proliferation in a breast cancer cell line harboring FGFR1 amplification in culture (PMID: 32973082).
|
32973082
|
|
FGFR1 amp
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Phase I |
Actionable |
In a Phase I trial (FOENIX-101), Lytgobi (futibatinib) treatment demonstrated manageable safety profile, and resulted in a partial response in 6% (5/86) and stable disease in 48% (41/86) of patients with advanced solid tumors harboring FGF/FGFR aberrations, among whom 20% (15/74) harbored FGFR1 amplification (PMID: 32622884; NCT02052778).
|
32622884
|
|
FGFR1 amp
|
lung squamous cell carcinoma
|
no benefit
|
RO5126766
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).
|
26438159
|
|
FGFR1 amp
|
lung non-small cell carcinoma
|
no benefit
|
RO5126766
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).
|
26438159
|
|
FGFR1 amp
|
lung small cell carcinoma
|
no benefit
|
RO5126766
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).
|
26438159
|
|
FGFR1 amp
|
triple-receptor negative breast cancer
|
no benefit
|
Rogaratinib
|
Preclinical - Pdx |
Actionable |
In a preclinical study, Rogaratinib (BAY 1163877) treatment did not inhibit tumor growth in a patient-derived xenograft (PDX) model of triple-negative breast cancer with FGFR1 amplification (PMID: 34593528).
|
34593528
|
|
FGFR1 amp
|
lung cancer
|
sensitive
|
GSK3052230
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, GSK3052230 (FP-1039) treatment resulted in greater tumor growth inhibition (56% vs 22%) in cell line xenograft models of FGFR1 amplified lung cancer compared to FGFR1 non-amplified models (PMID: 23536011).
|
23536011
|
|
FGFR1 amp
|
lung non-small cell carcinoma
|
sensitive
|
GSK3052230
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, GSK3052230 (FP-1039) treatment inhibited growth of FGFR1 amplified non-small cell lung carcinoma cell lines in culture and in cell line xenograft models (PMID: 23536011).
|
23536011
|
|
FGFR1 amp
|
lung small cell carcinoma
|
sensitive
|
GSK3052230
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, GSK3052230 (FP-1039) treatment inhibited growth of FGFR1 amplified lung small cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 23536011).
|
23536011
|
|
FGFR1 amp
|
adrenocortical carcinoma
|
sensitive
|
Derazantinib
|
Phase I |
Actionable |
In a Phase I trial, ARQ 087 treatment resulted in stable disease with a tumor reduction of 20% in an adrenocortical carcinoma patient harboring FGFR1 amplification, who remained on study for 3.5 years (PMID: 28972963; NCT01752920).
|
28972963
|
|
FGFR1 amp
|
lung cancer
|
sensitive
|
PD173074
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, lung cancer cells harboring FGFR1 amplification were sensitive to PD173074 treatment in culture, demonstrating inhibition of cell growth (PMID: 30140389).
|
30140389
|
|
FGFR1 amp
|
synovial sarcoma
|
sensitive
|
PD173074
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, PD173074 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980).
|
27535980
|
|
FGFR1 amp
|
lung non-small cell carcinoma
|
sensitive
|
PRN1371
|
Preclinical - Pdx |
Actionable |
In a preclinical study, PRN1371 treatment resulted in 96.1% tumor growth inhibition in patient-derived xenograft models of FGFR1-amplified non-small cell lung cancer (PMID: 28978721).
|
28978721
|
|
FGFR1 amp
|
lung adenocarcinoma
|
sensitive
|
PRN1371
|
Preclinical - Pdx |
Actionable |
In a preclinical study, PRN1371 treatment resulted in 64.6% tumor growth inhibition in patient-derived xenograft models of FGFR1-amplified lung adenocarcinoma (PMID: 28978721).
|
28978721
|
|
FGFR1 amp
|
lung non-small cell carcinoma
|
sensitive
|
Infigratinib + Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Truseltiq (infigratinib) and Mekinist (trametinib) combination treatment inhibited Erk signaling and growth of FGFR1-amplified non-small cell lung carcinoma cells in culture (PMID: 28630215).
|
28630215
|
|
FGFR1 amp
|
lung non-small cell carcinoma
|
sensitive
|
E7090
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, a non-small cell lung cancer cell line, harboring FGFR1 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969).
|
27535969
|
|
FGFR1 amp
|
lung small cell carcinoma
|
sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a small cell lung cancer cell line harboring FGFR1 amplification demonstrated sensitivity to E7090, resulting in decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969).
|
27535969
|
|
FGFR1 amp
|
estrogen-receptor positive breast cancer
|
sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring FGFR1 amplification (PMID: 7506125) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969).
|
7506125
27535969
|
|
FGFR1 amp
|
lung non-small cell carcinoma
|
predicted - sensitive
|
NGI-1
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, NGI-1 inhibited FGFR1 phosphorylation and proliferation of a FGFR1-amplified cell line dependent on FGFR1 signaling in culture, however, did not inhibit proliferation of an FGFR1-amplified cell line not dependent on FGFR1 signaling (PMID: 27694802).
|
27694802
|
|
FGFR1 amp
|
transitional cell carcinoma
|
sensitive
|
Buparlisib + Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) worked synergistically to induce apoptosis and inhibit growth of a urothelial cell carcinoma cell line with FGFR1 amplification in culture, with increased efficacy over either agent alone (PMID: 28108151).
|
28108151
|
|
FGFR1 amp
|
lung squamous cell carcinoma
|
sensitive
|
Buparlisib + Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) induced apoptosis in a squamous cell lung cancer cell line with amplification of FGFR1 in culture (PMID: 28108151).
|
28108151
|
|
FGFR1 amp
|
lung small cell carcinoma
|
sensitive
|
Buparlisib + Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) induced apoptosis in a small cell lung cancer cell line with amplification of FGFR1 in culture (PMID: 28108151).
|
28108151
|
|
FGFR1 amp
|
lung small cell carcinoma
|
sensitive
|
Cisplatin + Etoposide + GSK3052230
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, addition of GSK3052230 (FP-1039) to Platinol (cisplatin) and Vepesid (etoposide) resulted in improved tumor growth inhibition in cell line xenograft models of FGFR1 amplified lung small cell carcinoma (PMID: 23536011).
|
23536011
|
|
FGFR1 amp
|
lung large cell carcinoma
|
sensitive
|
ODM-203
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, ODM-203 inhibited FGFR signaling and proliferation in a large cell lung cancer cell line with amplification of chromosome 8p12 leading to increased FGFR1 copy number, and inhibited tumor growth in xenograft models (PMID: 30301864).
|
30301864
|
|
FGFR1 amp
|
Advanced Solid Tumor
|
predicted - sensitive
|
Olverembatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Olverembatinib (HQP1351) treatment inhibited cell growth, Fgfr1 phosphorylation, and downstream pathway signaling in cell lines with FGFR1 amplification in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 amp
|
lung non-small cell carcinoma
|
sensitive
|
Zotatifin
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Zotatifin (eFT226) inhibited tumor growth in a cell line xenograft model of FGFR1-amplified non-small cell lung cancer (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B133).
|
detail...
|
|
FGFR1 amp
|
lung squamous cell carcinoma
|
predicted - sensitive
|
Carboplatin + GSK3052230 + Paclitaxel
|
Phase I |
Actionable |
In a Phase Ib trial, the combination therapy of GSK3052230 (FP-1039), Taxol (paclitaxel), and Paraplatin (carboplatin) demonstrated safety and was well-tolerable, and resulted in an overall response rate of 47% (9/19), with 9 patients achieving a partial response, and a progression-free survival of 5.5 months in patients with stage IV or recurrent metastatic squamous non-small cell lung cancer harboring FGFR1 amplification (PMID: 31446228; NCT01868022).
|
31446228
|
|
FGFR1 amp
|
lung non-small cell carcinoma
|
sensitive
|
CPL304110
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, CPL304110 treatment inhibited proliferation of a non-small cell lung cancer cell line harboring FGFR1 amplification in culture (PMID: 33199155).
|
33199155
|
|
FGFR1 amp
|
lung cancer
|
sensitive
|
3D185
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, 3D185 inhibited downstream signaling and proliferation of a lung cancer cell line harboring FGFR1 amplification in culture and inhibited signaling and induced dose-dependent tumor growth inhibition in a cell line xenograft model (PMID: 31438996).
|
31438996
|
|
FGFR1 amp FGFR2 amp
|
breast cancer
|
sensitive
|
Regorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, a breast cancer cell line with FGFR1 and FGFR2 amplification was sensitive to treatment with Stivarga (regorafenib), demonstrating inhibition of cell growth in culture (PMID: 33563752).
|
33563752
|
|
FGFR1 amp FGFR2 amp
|
breast cancer
|
sensitive
|
Futibatinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Lytgobi (futibatinib) treatment led to inhibition of cell proliferation in breast cancer cell lines harboring FGFR1 and FGFR2 amplification in culture, and led to inhibition of tumor growth in a cell line xenograft model (PMID: 32973082).
|
32973082
|
|
FGFR1 amp FGFR2 amp
|
breast cancer
|
sensitive
|
E7090
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, a breast cancer cell line, harboring FGFR1 amplification and FGFR2 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969).
|
27535969
|
|
FGFR1 amp NRAS amp
|
lung non-small cell carcinoma
|
resistant
|
Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, non-small cell lung carcinoma cells harboring both FGFR1 and NRAS amplification were resistant to Mekinist (trametinib) in culture (PMID: 28630215).
|
28630215
|
|
FGFR1 amp NRAS amp
|
lung non-small cell carcinoma
|
resistant
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, amplification of NRAS was identified in a non-small cell lung cancer cell line harboring FGFR1 amplification that acquired resistance to Truseltiq (infigratinib) in culture (PMID: 28630215).
|
28630215
|
|
FGFR1 amp NRAS amp
|
lung non-small cell carcinoma
|
sensitive
|
Infigratinib + Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Truseltiq (infigratinib) and Mekinist (trametinib) combination treatment inhibited Erk signaling, resulting in growth inhibition in non-small cell lung carcinoma cells harboring both FGFR1 and NRAS amplification in culture (PMID: 28630215).
|
28630215
|
|
FGFR1 amp NRAS over exp
|
lung non-small cell carcinoma
|
decreased response
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, overexpression of Nras in FGFR1-amplified non-small cell lung carcinoma cells resulted in decreased response to Truseltiq (infigratinib) in culture (PMID: 28630215).
|
28630215
|
|
FGFR1 amp NRAS over exp
|
lung non-small cell carcinoma
|
sensitive
|
Infigratinib + Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Truseltiq (infigratinib) and Mekinist (trametinib) combination treatment inhibited Erk signaling, resulting in growth inhibition in FGFR1-amplified non-small cell lung carcinoma cells overexpressing Nras in culture (PMID: 28630215).
|
28630215
|
|
EML4 - ALK FGFR1 amp
|
lung non-small cell carcinoma
|
predicted - resistant
|
Brigatinib
|
Case Reports/Case Series |
Actionable |
In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK treated with Alunbrig (brigatinib) responded, but eventually progressed, and was subsequently found to harbor a presumed resistance alteration, FGFR1 amplification (PMID: 29636358).
|
29636358
|
|
FGFR2 fusion FGFR1 amp
|
colon cancer
|
predicted - sensitive
|
Zoligratinib
|
Case Reports/Case Series |
Actionable |
In a Phase I trial, Debio 1347 treatment resulted in a partial response with 49.5% reduction of tumor size and 66% decrease of DUSP6 score in a patient with colon cancer harboring FGFR1 amplification and FGFR2 fusion (PMID: 30745300; NCT01948297).
|
30745300
|
|
FGFR1 amp FGFR1 over exp
|
lung cancer
|
sensitive
|
Rogaratinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, treatment with Rogaratinib (BAY 1163877) in a lung cancer cell line xenograft model with FGFR1 amplification and FGFR1 overexpression resulted in inhibition of tumor growth (PMID: 30807645).
|
30807645
|
|
FGFR1 amp FGFR1 over exp
|
lung cancer
|
sensitive
|
Docetaxel + Rogaratinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, treatment with Rogaratinib (BAY 1163877) and Taxotere (docetaxel) resulted in an increased percentage of partial responses from 40% to 70% and one complete response compared to Taxotere (docetaxel) alone in lung cancer cell line xenograft models with FGFR1 amplification and FGFR1 overexpression (PMID: 30807645).
|
30807645
|
|
FGFR1 amp FGFR1 over exp
|
lung cancer
|
sensitive
|
Carboplatin + Paclitaxel + Rogaratinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, the combination therapy of Rogaratinib (BAY 1163877), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in an increased percentage of partial responses, from 30% to 70%, when compared to chemotherapy alone in lung cancer cell line xenograft models with FGFR1 amplification and FGFR1 overexpression (PMID: 30807645).
|
30807645
|
|
FGFR1 W4C FGFR1 amp
|
estrogen-receptor positive breast cancer
|
predicted - sensitive
|
Lucitanib
|
Preclinical - Pdx |
Actionable |
In a preclinical study, Lucitanib (E-3810) treatment resulted in reduced tumor volume in an ER-positive breast cancer patient-derived xenograft (PDX) model harboring FGFR1 W4C and FGFR1 amplification (PMID: 34593528).
|
34593528
|
|
FGFR1 W4C FGFR1 amp
|
estrogen-receptor positive breast cancer
|
no benefit
|
Rogaratinib
|
Preclinical - Pdx |
Actionable |
In a preclinical study, Rogaratinib (BAY 1163877) treatment did not inhibit tumor growth in an ER-positive breast cancer patient-derived xenograft (PDX) model with FGFR1 W4C and FGFR1 amplification (PMID: 34593528).
|
34593528
|
|
FGFR1 K656E
|
high grade glioma
|
predicted - sensitive
|
Infigratinib
|
Case Reports/Case Series |
Actionable |
In a Phase II trial, Truseltiq (infigratinib) treatment resulted in limited efficacy with a 6-month progression-free survival (PFS) rate of 16.0%, a median PFS of 1.7 months, an objective response rate of 4.8% (1/21), and median overall survival of 6.7 months in patients with recurrent glioma harboring alterations in FGFR1 or FGFR3; however, resulted in a partial response with PFS of 21.9 months and stable disease with PFS of 13.2 months in two patients harboring FGFR1 K656E (PMID: 35344029; NCT01975701).
|
35344029
|
|
FGFR1 K656E
|
Advanced Solid Tumor
|
conflicting
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 K656E demonstrated insensitivity to Truseltiq (infigratinib) in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 K656E
|
Advanced Solid Tumor
|
conflicting
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 K656E were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 K656E
|
Advanced Solid Tumor
|
predicted - resistant
|
Dovitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 K656E were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 K656E
|
low grade glioma
|
predicted - sensitive
|
Erdafitinib
|
Case Reports/Case Series |
Actionable |
In a Phase II trial (RAGNAR), treatment with Balversa (erdafitinib) resulted in a complete response with a duration of response of 21.68 months in a patient with low grade glioma harboring FGFR1 K656E (PMID: 37541273; NCT04083976).
|
37541273
|
|
FGFR1 K656E
|
Advanced Solid Tumor
|
conflicting
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 K656E demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 K656E
|
Advanced Solid Tumor
|
conflicting
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 K656E were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 K656E
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lytgobi (futibatinib) inhibited growth of a cell line expressing FGFR1 K656E in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 K656E
|
diffuse astrocytoma
|
predicted - sensitive
|
Pemigatinib
|
Case Reports/Case Series |
Actionable |
In a Phase II trial (FIGHT-207), Pemazyre (pemigatinib) treatment resulted in a partial response with an 80.7% decrease in target lesion and a progression-free survival of 8 months in a patient with diffuse astrocytoma harboring FGFR1 K656E (Cancer Res (2023) 83 (8_Supplement): CT016; NCT03822117).
|
detail...
|
|
FGFR1 K656E
|
Advanced Solid Tumor
|
conflicting
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 K656E demonstrated insensitivity to Pemazyre (pemigatinib) in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 K656E
|
Advanced Solid Tumor
|
conflicting
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 K656E were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 K656E
|
Advanced Solid Tumor
|
predicted - sensitive
|
Olverembatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Olverembatinib (HQP1351) inhibited growth of a cell line expressing FGFR1 K656E in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 act mut
|
Advanced Solid Tumor
|
sensitive
|
Dovitinib
|
Preclinical |
Actionable |
In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).
|
22238366
|
|
FGFR1 act mut
|
Advanced Solid Tumor
|
decreased response
|
Nintedanib
|
Preclinical |
Actionable |
In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).
|
22238366
|
|
FGFR1 act mut
|
Advanced Solid Tumor
|
sensitive
|
Ponatinib
|
Preclinical |
Actionable |
In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).
|
22238366
|
|
FGFR1 act mut
|
Advanced Solid Tumor
|
no benefit
|
Brivanib
|
Preclinical |
Actionable |
In a preclinical study, Brivanib (BMS-540215) did not inhibit receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).
|
22238366
|
|
FGFR1 act mut
|
Advanced Solid Tumor
|
decreased response
|
Cediranib
|
Preclinical |
Actionable |
In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).
|
22238366
|
|
FGFR1 act mut
|
Advanced Solid Tumor
|
sensitive
|
Zoligratinib
|
Phase I |
Actionable |
In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR1 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).
|
detail...
|
|
FGFR1 act mut
|
central nervous system benign neoplasm
|
predicted - sensitive
|
Erdafitinib
|
Case Reports/Case Series |
Actionable |
In a Phase II trial (MATCH), Balversa (erdafitinib) was tolerated and resulted in a partial response (PR) in 10% (2/20) and stable disease (SD) in 30% (6/20) of heavily pre-treated pediatric patients with low-grade gliomas or glioneuronal tumors harboring activating mutations in FGFR1 (n=16), FGFR2 (n=1), FGFR4 (n=1), or FGFR1 fusions (n=2), with a 6-mo overall survival rate of 89.7%, 2 PR and 4 SD were observed in patients with FGFR1 mutations (J Clin Oncol 41, 2023 (suppl 16; abstr 10007); NCT03210714).
|
detail...
|
|
FGFR1 act mut
|
low grade glioma
|
predicted - sensitive
|
Erdafitinib
|
Case Reports/Case Series |
Actionable |
In a Phase II trial (MATCH), Balversa (erdafitinib) was tolerated and resulted in a partial response (PR) in 10% (2/20) and stable disease (SD) in 30% (6/20) of heavily pre-treated pediatric patients with low-grade gliomas or glioneuronal tumors harboring activating mutations in FGFR1 (n=16), FGFR2 (n=1), FGFR4 (n=1), or FGFR1 fusions (n=2), with a 6-mo overall survival rate of 89.7%, 2 PR and 4 SD were observed in patients with FGFR1 mutations ( (J Clin Oncol 41, 2023 (suppl 16; abstr 10007); NCT03210714).
|
detail...
|
|
FGFR1 act mut
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Phase I |
Actionable |
In a Phase I trial, Balversa (erdafitinib) treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363; NCT01703481).
|
26324363
|
|
FGFR1 act mut
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Phase II |
Actionable |
In a Phase II trial (RAGNAR), Balversa (erdafitinib) treatment resulted in an objective response rate of 29.5% (64/217, 6 complete and 58 partial responses), a disease control rate of 74%, clinical benefit rate of 46%, a median duration of response of 6.9 months, median progression-free survival of 4.2 months, and median overall survival of 10.7 months in patients with advanced solid tumors harboring FGFR1, FGFR2, or FGFR3 mutations or fusions (PMID: 37541273; NCT04083976).
|
37541273
|
|
FGFR1 act mut
|
breast cancer
|
sensitive
|
FIIN-1
|
Preclinical |
Actionable |
In a preclinical study, FIIN-1 inhibited Fgfr1 activation-induced proliferation and transformation of human breast epithelial cell lines in culture (PMID: 20338520).
|
20338520
|
|
FGFR1 act mut
|
transitional cell carcinoma
|
no benefit
|
Derazantinib
|
Phase Ib/II |
Actionable |
In a Phase I/II trial (FIDES-02), Derazantinib (ARQ 087) treatment was well tolerated but demonstrated limited efficacy in patients with urothelial carcinoma harboring FGFR1 (n=4), FGFR2 (n=7), or FGFR3 (n=35) mutations or FGFR3 fusions (n=6), with an objective response rate of 8.2% (4/49, all partial responses) and disease control rate of 30.6% (15/49) by independent central review (PMID: 38627238; NCT04045613).
|
38627238
|
|
FGFR1 mutant
|
Advanced Solid Tumor
|
predicted - sensitive
|
Zoligratinib
|
Phase I |
Actionable |
In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).
|
30745300
|
|
FGFR1 mutant
|
transitional cell carcinoma
|
predicted - sensitive
|
Erdafitinib
|
Phase II |
Actionable |
In a Phase II trial, Balversa (erdafitinib) treatment resulted in an objective response rate of 42% (40/96, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations (J Clin Oncol 36, 2018 (suppl; abstr 4503); NCT02365597).
|
detail...
|
|
FGFR1 mutant
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Case Reports/Case Series |
Actionable |
In a Phase II trial (MATCH), Balversa (erdafitinib) treatment resulted in an objective response rate of 16% (4/25), median progression-free survival of 3.6 months, and median overall survival of 11.0 months in patients with advanced solid tumors harboring FGFR1, FGFR2, or FGFR3 mutations or fusions (PMID: 38603650; NCT02465060).
|
38603650
|
|
FGFR1 mutant
|
Advanced Solid Tumor
|
sensitive
|
Pemigatinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to Pemazyre (pemigatinib) in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771).
|
detail...
|
|
FGFR1 mutant
|
Advanced Solid Tumor
|
predicted - sensitive
|
ICP-192
|
Phase I |
Actionable |
In a Phase I trial, ICP-192 (gunagratinib) was well-tolerated, and resulted in an overall response rate or 33.3% (4/12, 1 complete response, 3 partial response) and a disease control rate of 91.7% (11/12) in patients with advanced solid tumors harboring FGF/FGFR gene aberrations (J Clin Oncol 39, 2021 (suppl 15; abstr 4092); NCT03758664).
|
detail...
|
|
FGFR1 rearrange
|
leukemia
|
sensitive
|
Fexagratinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, AZD4547 inhibited survival of leukemia cells harboring FGFR1 translocation in culture and in cell line xenograft models (PMID: 27550940).
|
27550940
|
|
FGFR1 rearrange
|
lung small cell carcinoma
|
sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, AZD4547 inhibited survival of small cell lung cancer cells harboring FGFR1 translocation in culture (PMID: 27550940).
|
27550940
|
|
FGFR1 rearrange
|
myeloproliferative neoplasm
|
sensitive
|
Dovitinib
|
Preclinical |
Actionable |
In a preclinical study, primary cells from 8p11 myeloproliferative syndrome patients harboring FGFR1 rearrangement were sensitive to Dovitinib (TKI258)-induced growth inhibition in culture (PMID: 17698633).
|
17698633
|
|
FGFR1 rearrange
|
myeloid and lymphoid neoplasms associated with FGFR1 abnormalities
|
sensitive
|
Midostaurin
|
Guideline |
Actionable |
Rydapt (midostaurin) is included in guidelines for patients with a myeloid/lymphoid neoplasm with eosinophilia harboring an FGFR1 rearrangement (NCCN.org).
|
detail...
|
|
FGFR1 rearrange
|
myeloid and lymphoid neoplasms associated with FGFR1 abnormalities
|
sensitive
|
Ponatinib
|
Guideline |
Actionable |
Iclusig (ponatinib) is included in guidelines for patients with a myeloid/lymphoid neoplasm with eosinophilia harboring an FGFR1 rearrangement (NCCN.org).
|
detail...
|
|
FGFR1 rearrange
|
cholangiocarcinoma
|
predicted - sensitive
|
Erdafitinib
|
Case Reports/Case Series |
Actionable |
In a Phase II trial, Balversa (erdafitinib) treatment resulted in a confirmed objective response rate (ORR) of 40.9% (9/22, 1 complete, 8 partial responses), a median progression-free survival of 5.6 months, and median overall survival of 25.8 months in patients with cholangiocarcinoma harboring an FGFR rearrangement or FGFR short variant, with an ORR of 57.1% (8/14) with FGFR rearrangement and 12.5% (1/8) with FGFR short variant (PMID: 39138436; NCT02699606).
|
39138436
|
|
FGFR1 rearrange
|
childhood B-cell acute lymphoblastic leukemia
|
not applicable
|
N/A
|
Guideline |
Prognostic |
FGFR1 rearrangements are associated with a poor prognosis in pediatric patients with B-cell acute lymphoblastic leukemia (NCCN.org).
|
detail...
|
|
FGFR1 rearrange
|
B-cell acute lymphoblastic leukemia
|
not applicable
|
N/A
|
Guideline |
Prognostic |
FGFR1 rearrangements are associated with a poor prognosis in patients with B-cell acute lymphoblastic leukemia (NCCN.org).
|
detail...
|
|
FGFR1 rearrange
|
myeloid and lymphoid neoplasms associated with FGFR1 abnormalities
|
sensitive
|
Pemigatinib
|
FDA approved |
Actionable |
In a Phase II trial (FIGHT-203) that supported FDA approval, Pemazyre (pemigatinib) treatment resulted in a complete response rate of 64.5% (20/31) and a complete cytogenetic response rate of 72.2% (24/33) in adult patients with relapsed or refractory myeloid or lymphoid neoplasms harboring FGFR1 rearrangements, with median duration of complete response not reached (Blood (2021) 138 (Supplement 1): 385; NCT03011372).
|
detail...
detail...
|
|
FGFR1 rearrange
|
myeloid and lymphoid neoplasms associated with FGFR1 abnormalities
|
sensitive
|
Pemigatinib
|
Guideline |
Actionable |
Pemazyre (pemigatinib) is included in guidelines (category 2A) for patients with a myeloid/lymphoid neoplasm with eosinophilia harboring an FGFR1 rearrangement (NCCN.org).
|
detail...
|
|
FGFR1 R250W
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R250W
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R250W
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R250W
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R250W
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R250W
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R250W were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S125L
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S125L
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S125L
|
Advanced Solid Tumor
|
predicted - resistant
|
Dovitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S125L were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 S125L
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S125L
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S125L
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S125L
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S125L were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 over exp
|
uterus leiomyosarcoma
|
sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, AZD4547 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980).
|
27535980
|
|
FGFR1 over exp
|
intrahepatic cholangiocarcinoma
|
no benefit
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, an intrahepatic cholangiocarcinoma cell line overexpressing FGFR1 was not sensitive to Truseltiq (infigratinib) in culture (PMID: 35420673).
|
35420673
|
|
FGFR1 over exp
|
uterus leiomyosarcoma
|
sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Truseltiq (infigratinib) inhibited survival of FGFR1-overexpressing uterus leiomyosarcoma cells in culture (PMID: 27535980).
|
27535980
|
|
FGFR1 over exp
|
head and neck squamous cell carcinoma
|
sensitive
|
Infigratinib
|
Preclinical |
Actionable |
In a preclinical study, Truseltiq (infigratinib) inhibited cell growth and induced apoptosis in HNSCC cells over expressing Fgfr1 in culture and in xenograft models (PMID: 26015511).
|
26015511
|
|
FGFR1 over exp
|
stomach cancer
|
sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Truseltiq (infigratinib) treatment inhibited growth of FGFR1-overexpressing gastric cancer cells in culture (PMID: 33563752).
|
33563752
|
|
FGFR1 over exp
|
thyroid cancer
|
sensitive
|
Lenvatinib
|
Preclinical |
Actionable |
In a preclinical study, Lenvima (lenvatinib) inhibited FGFR1 phosphorylation and signaling in thyroid cancer cells overexpressing FGFR1 (PMID: 25295214).
|
25295214
|
|
FGFR1 over exp
|
stomach cancer
|
sensitive
|
Regorafenib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, treatment with Stivarga (regorafenib) in an FGFR1-overexpressing gastric cancer cell line resulted in decreased phosphorylation of Fgfr2 and Erk, and inhibition of cell growth in culture (PMID: 33563752).
|
33563752
|
|
FGFR1 over exp
|
renal cell carcinoma
|
not applicable
|
Sorafenib
|
Phase II |
Emerging |
In a clinical analysis of a Phase II trial, high Fgfr1 expression level was associated with decreased progression free survival in renal cell carcinoma patients treated with Nexavar (sorafenib) (PMID: 25900027).
|
25900027
|
|
FGFR1 over exp
|
stomach cancer
|
sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Balversa (erdafitinib) treatment inhibited growth of gastric cancer cells overexpressing FGFR1 in culture (PMID: 33563752).
|
33563752
|
|
FGFR1 over exp
|
Her2-receptor negative breast cancer
|
predicted - sensitive
|
Lucitanib
|
Phase II |
Actionable |
In a Phase II (FINESSE) trial, Lucitanib (E-3810) treatment resulted in improved objective response rate (25%, 5/20 vs 8%, 3/39) and median progression-free survival (158 vs 109 days) in patients with metastatic hormone receptor-positive, Erbb2 (Her2)-negative breast cancer with high Fgfr1 expression (H-score>=50) compared to those with low Fgfr1 expression (H-score<50) (PMID: 31619444; NCT02053636).
|
31619444
|
|
FGFR1 over exp
|
intrahepatic cholangiocarcinoma
|
no benefit
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, an intrahepatic cholangiocarcinoma cell line overexpressing FGFR1 was not sensitive to Lytgobi (futibatinib) in culture (PMID: 35420673).
|
35420673
|
|
FGFR1 over exp
|
stomach cancer
|
sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lytgobi (futibatinib) treatment inhibited growth of FGFR1-overexpressing gastric cancer cells in culture (PMID: 33563752).
|
33563752
|
|
FGFR1 over exp
|
colon cancer
|
sensitive
|
Rogaratinib
|
Preclinical |
Actionable |
In a preclinical study, syngeneic colon cancer mouse models with FGFR1 over expression demonstrated antitumor activity when treated with Rogaratinib (BAY 1163877), with a partial response observed in 22% (2/9) and stable disease in one (PMID: 30807645).
|
30807645
|
|
FGFR1 over exp
|
lung cancer
|
predicted - sensitive
|
Rogaratinib
|
Preclinical - Pdx |
Actionable |
In a preclinical study, a lung cancer patient-derived xenograft (PDX) model with FGFR1 overexpression demonstrated decreased tumor volume when treated with Rogaratinib (BAY 1163877) (PMID: 30807645).
|
30807645
|
|
FGFR1 over exp
|
transitional cell carcinoma
|
no benefit
|
Rogaratinib
|
Phase II |
Actionable |
In a Phase II trial (FORT-1), Rogaratinib (BAY 1163877) treatment did not result in improved outcomes compared to chemotherapy in advanced or metastatic urothelial carcinoma patients with FGFR1 or FGFR3 overexpression, with similar median overall survival (8.3 mo vs 9.8 mo), median progression-free survival (2.7 mo vs. 3.2 mo), and objective response rate (20.7% (18/87) vs 19.3% (17/88)), failing to meet the predetermined criteria for continuation to Phase III (PMID: 36240478; NCT03410693).
|
36240478
|
|
FGFR1 over exp
|
lung squamous cell carcinoma
|
no benefit
|
Rogaratinib
|
Phase II |
Actionable |
In a Phase II trial (SAKK 19/18), Rogaratinib (BAY 1163877) treatment did not meet its primary endpoint for 6-month progression-free survival (PFS) in patients with advanced lung squamous cell carcinoma harboring overexpression of FGFR1, FGFR2, or FGFR3, and resulted in only 6.7% (1/15) of patients achieving 6-month PFS, with no objective responses, a median PFS of 1.6 months, and a median overall survival of 3.5 months (PMID: 36099710; NCT03762122).
|
36099710
|
|
FGFR1 over exp
|
Advanced Solid Tumor
|
predicted - sensitive
|
Rogaratinib
|
Phase I |
Actionable |
In a Phase I trial, treatment with Rogaratinib (BAY 1163877) was well-tolerated and resulted in objective response rate (ORR) of 15% (15/100) in patients with FGFR1, FGFR2, or FGFR3-overexpressing advanced solid tumors, including urothelial cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer, and led to an ORR of 67% (10/15) in patients with FGFR overexpression, but without an FGFR genetic aberration (PMID: 31405822; NCT01976741).
|
31405822
|
|
FGFR1 over exp
|
Advanced Solid Tumor
|
sensitive
|
Derazantinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells overexpressing Fgfr1 in culture (PMID: 27627808).
|
27627808
|
|
FGFR1 over exp
|
uterus leiomyosarcoma
|
sensitive
|
PD173074
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, PD173074 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980).
|
27535980
|
|
FGFR1 over exp
|
Advanced Solid Tumor
|
sensitive
|
PRN1371
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing wild-type FGFR1 in culture (PMID: 28978721).
|
28978721
|
|
FGFR1 over exp
|
intrahepatic cholangiocarcinoma
|
no benefit
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, an intrahepatic cholangiocarcinoma cell line overexpressing FGFR1 was not sensitive to Pemazyre (pemigatinib) in culture (PMID: 35420673).
|
35420673
|
|
FGFR1 over exp
|
stomach cancer
|
sensitive
|
Infigratinib + Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the addition of Mekinist (trametinib) restored sensitivity of gastric cancer cells with FGFR1 overexpression to Truseltiq (infigratinib) treatment, demonstrating decreased Erk phosphorylation and reduced cell proliferation in culture (PMID: 33563752).
|
33563752
|
|
FGFR1 over exp
|
lung cancer
|
predicted - sensitive
|
Docetaxel + Rogaratinib
|
Preclinical - Pdx |
Actionable |
In a preclinical study, the combination of Rogaratinib (BAY 1163877) and Taxotere (docetaxel) resulted in improved inhibition of tumor growth and duration of response, leading to three complete responses and seven partial responses compared to Taxotere (docetaxel) alone, resulting in only six partial responses, in lung cancer patient-derived xenograft models with FGFR1 overexpression (n=10) (PMID: 30807645).
|
30807645
|
|
FGFR1 over exp
|
stomach cancer
|
sensitive
|
Regorafenib + Trametinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the addition of Mekinist (trametinib) restored sensitivity of gastric cancer cells with FGFR1 overexpression to Stivarga (regorafenib) treatment, demonstrating decreased Erk phosphorylation and reduced cell proliferation in culture (PMID: 33563752).
|
33563752
|
|
FGFR1 over exp PIK3CA mut
|
estrogen-receptor positive breast cancer
|
sensitive
|
Alpelisib + Lucitanib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, an estrogen-receptor positive breast cancer cell line over expressing FGFR1 and expressing a PIK3CA mutation demonstrated sensitivity to the combination of Alpelisib (BYL719) and Lucitanib (E-3810) in culture (PMID: 27126994).
|
27126994
|
|
FGFR1 N546K
|
Advanced Solid Tumor
|
predicted - resistant
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 N546K were resistant to treatment with AZD4547 in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 N546K
|
diffuse midline glioma, H3 K27M-mutant
|
sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Truseltiq (infigratinib) inhibited viability of mouse glioma cells expressing H3.3 K28M (reported as H3.3 K27M) and FGFR1 N546K (reported as N457K) in culture (PMID: 37011011).
|
37011011
|
|
FGFR1 N546K
|
Advanced Solid Tumor
|
predicted - resistant
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 N546K were resistant to treatment with Truseltiq (infigratinib) in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 N546K
|
diffuse midline glioma, H3 K27M-mutant
|
sensitive
|
Alpelisib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Piqray (alpelisib) inhibited viability of mouse glioma cells expressing H3.3 K28M (reported as H3.3 K27M) and FGFR1 N546K (reported as N457K) in culture (PMID: 37011011).
|
37011011
|
|
FGFR1 N546K
|
Advanced Solid Tumor
|
predicted - resistant
|
Dovitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 N546K were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 N546K
|
Advanced Solid Tumor
|
predicted - resistant
|
Erdafitinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, cells expressing FGFR1 N546K were resistant to treatment with Balversa (erdafitinib) in culture, and Balversa (erdafitinib) treatment did not lead to tumor growth inhibition in a cell line xenograft model (PMID: 34272467).
|
34272467
|
|
FGFR1 N546K
|
Advanced Solid Tumor
|
predicted - resistant
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 N546K were resistant to treatment with Lytgobi (futibatinib) in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 N546K
|
pilocytic astrocytoma
|
predicted - sensitive
|
Pemigatinib
|
Case Reports/Case Series |
Actionable |
In a Phase I trial (FIGHT-101), Pemazyre (pemigatinib) treatment resulted in a partial response with a 52% decrease in tumor size at first restaging and a 91% tumor reduction after 13 cycles in a patient with pilocytic astrocytoma harboring FGFR1 N546K, with the response lasting 18 months (PMID: 35507888; NCT02393248).
|
35507888
|
|
FGFR1 N546K
|
Advanced Solid Tumor
|
predicted - resistant
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 N546K were resistant to treatment with Pemazyre (pemigatinib) in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 N546K
|
neuroblastoma
|
sensitive
|
Fexagratinib + Pictilisib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of AZD4547 and Pictilisib (GDC-0941) resulted in greater inhibition of FGFR1 signaling, cell invasion, and colony formation compared to AZD4547 alone in neuroblastoma cell lines expressing FGFR1 N546K in culture (PMID: 35488346).
|
35488346
|
|
ALK F1174L FGFR1 N546K
|
neuroblastoma
|
predicted - resistant
|
Lorlatinib
|
Case Reports/Case Series |
Actionable |
In a Phase I trial, a neuroblastoma patient harboring ALK F1174L developed progressive disease on treatment with Lorbrena (lorlatinib) and was found to have acquired FGFR1 N546K via circulating tumor DNA (PMID: 37147298; NCT03107988).
|
37147298
|
|
FGFR1 fusion
|
acute myeloid leukemia
|
sensitive
|
Dovitinib
|
Preclinical |
Actionable |
In a preclinical study, Dovitinib (TKI258) increased apoptosis and inhibited survival of acute myelogenous leukemia cell lines harboring FGFR1OP2-FGFR1 fusion in culture (PMID: 17698633).
|
17698633
|
|
FGFR1 fusion
|
Advanced Solid Tumor
|
sensitive
|
Dovitinib
|
Preclinical |
Actionable |
In a preclinical study, Dovitinib (TKI258) inhibited Erk, Stat5 signaling and survival of transformed cell lines overexpressing FGFR1 fusion proteins (ZMYM2-FGFR1 or BCR-FGFR1) in culture (PMID: 17698633).
|
17698633
|
|
FGFR1 fusion
|
Advanced Solid Tumor
|
no benefit
|
Zoligratinib
|
Phase I |
Actionable |
In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).
|
30745300
|
|
FGFR1 fusion
|
Advanced Solid Tumor
|
no benefit
|
Zoligratinib
|
Phase II |
Actionable |
In a Phase II trial (FUZE), Debio 1347 treatment demonstrated manageable toxicity but limited efficacy in patients with advanced solid tumors harboring a fusion in FGFR1, FGFR2, or FGFR3, resulting in an objective response rate of 5% (3/58, all partial responses), with stable disease in in 45% (26/58) of patients, and a median progression-free survival of 3.55 months at a median follow-up of 3.6 months, and further enrollment to the trial was terminated due to lack of efficacy (PMID: 38771739; NCT03834220).
|
38771739
|
|
FGFR1 fusion
|
pancreatic cancer
|
predicted - sensitive
|
Erdafitinib
|
Case Reports/Case Series |
Actionable |
In a Phase II trial (RAGNAR), Balversa (erdafitinib) treatment resulted in an objective response rate of 56% (10/18), a disease control rate of 94%, median duration of response of 7.1 months, median progression-free survival of 7.0 months, and median overall survival of 19.7 months in patients with pancreatic cancer harboring FGFR1 (n=4) or FGFR2 (n=14) fusions (PMID: 37541273; NCT04083976).
|
37541273
|
|
FGFR1 fusion
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Case Reports/Case Series |
Actionable |
In a Phase II trial (MATCH), Balversa (erdafitinib) treatment resulted in an objective response rate of 16% (4/25), median progression-free survival of 3.6 months, and median overall survival of 11.0 months in patients with advanced solid tumors harboring FGFR1, FGFR2, or FGFR3 mutations or fusions (PMID: 38603650; NCT02465060).
|
38603650
|
|
FGFR1 fusion
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Phase II |
Actionable |
In a Phase II trial (RAGNAR), Balversa (erdafitinib) treatment resulted in an objective response rate of 29.5% (64/217, 6 complete and 58 partial responses), a disease control rate of 74%, clinical benefit rate of 46%, a median duration of response of 6.9 months, median progression-free survival of 4.2 months, and median overall survival of 10.7 months in patients with advanced solid tumors harboring FGFR1, FGFR2, or FGFR3 mutations or fusions (PMID: 37541273; NCT04083976).
|
37541273
|
|
FGFR1 fusion
|
hematologic cancer
|
sensitive
|
Derazantinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Derazantinib (ARQ 087) inhibited growth of hematologic cancer cells harboring FGFROP2-FGFR1 fusion in culture (PMID: 27627808).
|
27627808
|
|
FGFR1 fusion
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Phase II |
Actionable |
In a Phase II trial (FIGHT-207), Pemazyre (pemigatinib) treatment demonstrated safety in previously treated patients with advanced solid tumors harboring a fusion in FGFR1, FGFR2, or FGFR3, and resulted in an objective response rate of 26.5% (13/49, 1 complete and 12 partial responses), with a median duration of response of 7.8 months, a clinical benefit rate of 28.6%, a median progression-free survival of 4.5 months, and a median overall survival of 17.5 months (PMID: 38710951; NCT03822117).
|
38710951
|
|
FGFR1 V561M
|
lung non-small cell carcinoma
|
resistant
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, non-small cell lung cancer cells expressing FGFR1 V561M demonstrated resistance to AZD4547 in culture (PMID: 30257990).
|
30257990
|
|
FGFR1 V561M
|
Advanced Solid Tumor
|
predicted - resistant
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, treatment with Truseltiq (infigratinib) failed to inhibit cell growth and Fgfr1 downstream signaling in cells expressing FGFR1 V561M in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 V561M
|
Advanced Solid Tumor
|
predicted - resistant
|
Ponatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 V561M demonstrated insensitivity to Iclusig (ponatinib) in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 V561M
|
Advanced Solid Tumor
|
predicted - resistant
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 V561M demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 V561M
|
Advanced Solid Tumor
|
predicted - resistant
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, treatment with Lytgobi (futibatinib) failed to inhibit cell growth and Fgfr1 downstream signaling in cells expressing FGFR1 V561M in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 V561M
|
Advanced Solid Tumor
|
sensitive
|
FIIN-1
|
Preclinical - Biochemical |
Actionable |
In a preclinical study, FIIN-1 inhibited Fgfr1 autophosphorylation in a human transformed embryonic kidney cell line harboring FGFR1 V561M mutation in culture (PMID: 20338520).
|
20338520
|
|
FGFR1 V561M
|
Advanced Solid Tumor
|
sensitive
|
PRN1371
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing FGFR1 V561M in culture (PMID: 28978721).
|
28978721
|
|
FGFR1 V561M
|
Advanced Solid Tumor
|
predicted - resistant
|
Pemigatinib
|
Preclinical - Biochemical |
Actionable |
In a preclinical study, a cell line expressing FGFR1 V561M was resistant to Pemazyre (pemigatinib) in a kinase assay (PMID: 36698015).
|
36698015
|
|
FGFR1 V561M
|
Advanced Solid Tumor
|
predicted - resistant
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, treatment with Pemazyre (pemigatinib) failed to inhibit cell growth and Fgfr1 downstream signaling in cells expressing FGFR1 V561M in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 V561M
|
Advanced Solid Tumor
|
sensitive
|
Olverembatinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Olverembatinib (HQP1351) treatment inhibited cell growth and Fgfr1 phosphorylation and downstream pathway activation in cells expressing FGFR1 V561M in culture and inhibited tumor growth in cell line xenograft models, with a tumor growth inhibition of 49.8% (PMID: 34114373).
|
34114373
|
|
FGFR1 V561M
|
Advanced Solid Tumor
|
predicted - sensitive
|
3D185
|
Preclinical - Biochemical |
Actionable |
In a preclinical study, 3D185 inhibited kinase activity of FGFR1 V561M in an in vitro assay (PMID: 31438996).
|
31438996
|
|
FGFR1 A268S
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A268S were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 A268S
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A268S were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 A268S
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A268S were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 A268S
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A268S were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 A268S
|
Advanced Solid Tumor
|
predicted - resistant
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A268S were resistant to treatment with E7090 in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 K656M
|
Advanced Solid Tumor
|
predicted - resistant
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 K656M were resistant to treatment with AZD4547 in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 K656M
|
Advanced Solid Tumor
|
predicted - resistant
|
Dovitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 K656M were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 K656M
|
Advanced Solid Tumor
|
predicted - resistant
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 K656M were resistant to treatment with E7090 in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 K656N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Truseltiq (infigratinib) inhibited growth of a cell line expressing FGFR1 K656N in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 K656N
|
Advanced Solid Tumor
|
predicted - resistant
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 K656N demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 K656N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Lytgobi (futibatinib) inhibited growth of a cell line expressing FGFR1 K656N in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 K656N
|
Advanced Solid Tumor
|
predicted - resistant
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 K656N demonstrated insensitivity to Pemazyre (pemigatinib) in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 K656N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Olverembatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Olverembatinib (HQP1351) inhibited growth of a cell line expressing FGFR1 K656N in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 P150S
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 P150S were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 P150S
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 P150S were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 P150S
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 P150S were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 P150S
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 P150S were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T141R
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T141R were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T141R
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T141R were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T141R
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T141R were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T141R
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T141R were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T141R
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical |
Actionable |
In a preclinical study, cells expressing FGFR1 T141R were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T141R
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T141R were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 positive
|
leiomyosarcoma
|
decreased response
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).
|
27535980
|
|
FGFR1 positive
|
uterus leiomyosarcoma
|
decreased response
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).
|
27535980
|
|
FGFR1 positive
|
synovial sarcoma
|
decreased response
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).
|
27535980
|
|
FGFR1 positive
|
leiomyosarcoma
|
decreased response
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to Truseltiq (infigratinib) in culture (PMID: 27535980).
|
27535980
|
|
FGFR1 positive
|
uterus leiomyosarcoma
|
decreased response
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to Truseltiq (infigratinib) in culture (PMID: 27535980).
|
27535980
|
|
FGFR1 positive
|
synovial sarcoma
|
decreased response
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to Truseltiq (infigratinib) in culture (PMID: 27535980).
|
27535980
|
|
FGFR1 positive
|
hemangioma
|
predicted - sensitive
|
Rogaratinib
|
Case Reports/Case Series |
Actionable |
In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease with resolution of edema in a patient with FGFR1-positive hemangioendothelioma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).
|
detail...
|
|
FGFR1 positive
|
salivary gland adenoid cystic carcinoma
|
predicted - sensitive
|
Rogaratinib
|
Case Reports/Case Series |
Actionable |
In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including a partial response in a patient with FGFR1-positive adenoid cystic carcinoma of the tongue (PMID: 31405822; NCT01976741).
|
31405822
|
|
FGFR1 positive
|
leiomyosarcoma
|
decreased response
|
PD173074
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).
|
27535980
|
|
FGFR1 positive
|
uterus leiomyosarcoma
|
decreased response
|
PD173074
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).
|
27535980
|
|
FGFR1 positive
|
synovial sarcoma
|
decreased response
|
PD173074
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).
|
27535980
|
|
FGFR1 positive
|
lung adenocarcinoma
|
sensitive
|
AZD8055 + Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452).
|
26359452
|
|
FGFR1 positive
|
lung large cell carcinoma
|
sensitive
|
AZD8055 + Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452).
|
26359452
|
|
FGFR1 positive
|
lung adenocarcinoma
|
sensitive
|
Fexagratinib + Vistusertib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture and in cell line xenograft models (PMID: 26359452).
|
26359452
|
|
FGFR1 positive
|
lung large cell carcinoma
|
sensitive
|
Fexagratinib + Vistusertib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture and in cell line xenograft models (PMID: 26359452).
|
26359452
|
|
FGFR1 positive
|
head and neck squamous cell carcinoma
|
sensitive
|
Fexagratinib + Vistusertib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent head and neck squamous cell carcinoma cells in culture (PMID: 26359452).
|
26359452
|
|
FGFR1 positive
|
lung adenocarcinoma
|
sensitive
|
Fexagratinib + Sirolimus
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452).
|
26359452
|
|
FGFR1 positive
|
lung large cell carcinoma
|
sensitive
|
Fexagratinib + Sirolimus
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452).
|
26359452
|
|
FGFR1 positive
|
glioblastoma
|
sensitive
|
CYY292
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, CYY292 inhibited Fgfr1 downstream signaling, proliferation, migration, and invasion in Fgfr1-expressing glioblastoma cell lines in culture, inhibited tumor growth in a cell line xenograft model, and inhibited growth and improved survival in an orthotopic xenograft model of glioblastoma (PMID: 37588207).
|
37588207
|
|
FGFR1 pos FGFR2 pos
|
hepatocellular carcinoma
|
sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, hepatocellular carcinoma cell lines treated with AZD4547 demonstrated decreased phosphorylation of FGFR1 and FGFR2, reduced colony formation, and evidence of apoptotic activity in culture (PMID: 26351320).
|
26351320
|
|
FGFR1 pos FGFR2 pos
|
hepatocellular carcinoma
|
no benefit
|
PHA-665752
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, PHA-665752 treatment did not result in decreased colony formation or reduced phosphorylation levels of FGFR1 and FGFR2 in hepatocellular carcinoma cells in culture (PMID: 26351320).
|
26351320
|
|
FGFR1 N546D
|
intrahepatic cholangiocarcinoma
|
predicted - sensitive
|
Futibatinib
|
Case Reports/Case Series |
Actionable |
In a Phase I trial (FOENIX-101), Lytgobi (futibatinib) treatment resulted in a partial response in a patient with glioblastoma harboring FGFR1 N546D (PMID: 32622884; NCT02052778).
|
32622884
|
|
FGFR1 M563I FGFR1 K687E
|
oligodendroglioma
|
predicted - sensitive
|
Futibatinib
|
Case Reports/Case Series |
Actionable |
In a Phase I trial (FOENIX-101), Lytgobi (futibatinib) treatment resulted in a partial response in a patient with anaplastic oligodendroglioma harboring FGFR1 M563I and FGFR1 K687E (PMID: 32622884; NCT02052778).
|
32622884
|
|
FGFR1 V592M FGFR1 K687E
|
glioblastoma
|
predicted - sensitive
|
Zoligratinib
|
Case Reports/Case Series |
Actionable |
In a clinical case study, Debio 1347 treatment resulted in a near complete response with a 96.3% maximal tumor reduction after 2 months of therapy in a pediatric patient with spinal cord glioblastoma harboring FGFR1 V592M and FGFR1 K687E, and the response was maintained for 11 months (PMID: 34250399).
|
34250399
|
|
FGFR1 V592M FGFR1 K687E
|
pilomyxoid astrocytoma
|
predicted - sensitive
|
Zoligratinib
|
Case Reports/Case Series |
Actionable |
In a clinical case study, Debio 1347 treatment resulted in a significant clinical improvement and sustained stable disease at 14 months with a 12.2% maximal tumor reduction in a pediatric patient with optic pathway pilomyxoid astrocytoma harboring FGFR1 V592M and FGFR1 K687E (PMID: 34250399).
|
34250399
|
|
FGFR1 A21T
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A21T were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 A21T
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A21T were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 A21T
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A21T were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 A21T
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A21T were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 A21T
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A21T were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 A21T
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A21T were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D128N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D128N were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D128N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D128N were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D128N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D128N were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D128N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D128N were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D128N
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D128N were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D128V
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D128V were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D128V
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D128V were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D128V
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D128V were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D128V
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D128V were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D128V
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D128V were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D128V
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D128V were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D133N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D133N were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D133N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D133N were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D133N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D133N were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D133N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D133N were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D133N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D133N were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D133N
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D133N were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D320N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D320N were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D320N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D320N were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D320N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D320N were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D320N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D320N were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D320N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D320N were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 D320N
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 D320N were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 E592G
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 E592G were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 E592G
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 E592G were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 E592G
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 E592G were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 E592G
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 E592G were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 E592G
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 E592G were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R189C
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R189C were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R189C
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R189C were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R189C
|
Advanced Solid Tumor
|
predicted - resistant
|
Dovitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R189C were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 S238N
|
Advanced Solid Tumor
|
predicted - resistant
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S238N were resistant to treatment with AZD4547 in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 S238N
|
Advanced Solid Tumor
|
predicted - resistant
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S238N were resistant to treatment with Truseltiq (infigratinib) in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 S238N
|
Advanced Solid Tumor
|
predicted - resistant
|
Dovitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S238N were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 S238N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S238N were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S238N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S238N were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S238N
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S238N were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S238N
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S238N were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S436F
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S436F were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S436F
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S436F were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S436F
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S436F were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S436F
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S436F were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S436F
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S436F were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S436F
|
Advanced Solid Tumor
|
predicted - resistant
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S436F were resistant to treatment with E7090 in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 T319A
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T319A were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T319A
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T319A were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T319A
|
Advanced Solid Tumor
|
predicted - resistant
|
Dovitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T319A were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 T319A
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T319A were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T319A
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T319A were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T319A
|
Advanced Solid Tumor
|
predicted - resistant
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T319A were resistant to treatment with E7090 in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 T340M
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T340M were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T340M
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T340M were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T340M
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T340M were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T340M
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T340M were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T340M
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T340M were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T340M
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T340M were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 A121D
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 A121D
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 A121D
|
Advanced Solid Tumor
|
predicted - resistant
|
Dovitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A121D were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 A121D
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 A121D
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 A121D
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 A121D
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 A121D were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R445W
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R445W were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R445W
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R445W were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R445W
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R445W were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R445W
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R445W were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R445W
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R445W were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 M456V
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 M456V were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 M456V
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 M456V were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 M456V
|
Advanced Solid Tumor
|
predicted - resistant
|
Dovitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 M456V were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 M456V
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 M456V were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 M456V
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 M456V were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 M456V
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 M456V were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 M456V
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 M456V were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 E467K
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 E467K were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 E467K
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 E467K were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 E467K
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 E467K were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 E467K
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 E467K were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 E467K
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 E467K were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 E467K
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 E467K were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R475Q
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R475Q were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R475Q
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R475Q were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R475Q
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R475Q were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R475Q
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R475Q were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T26I
|
Advanced Solid Tumor
|
predicted - resistant
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T26I were resistant to treatment with AZD4547 in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 T26I
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T26I were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T26I
|
Advanced Solid Tumor
|
predicted - sensitive
|
Dovitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T26I were resistant to treatment with Dovitinib (TKI258) in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 T26I
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T26I were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T26I
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T26I were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 T26I
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 T26I were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S588T
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S588T were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S588T
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S588T were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S588T
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S588T were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S588T
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S588T were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 S588T
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 S588T were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 P483L
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 P483L were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 P483L
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 P483L were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 P483L
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 P483L were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 P483L
|
Advanced Solid Tumor
|
predicted - resistant
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 P483L were resistant to treatment with Lytgobi (futibatinib) in culture (PMID: 34272467).
|
34272467
|
|
FGFR1 P483L
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 P483L were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 P483L
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 P483L were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 G703S
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 G703S were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 G703S
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 G703S were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 G703S
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 G703S were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 G703S
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 G703S were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 G703S
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 G703S were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 V751A
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 V751A were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 V751A
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 V751A were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 V751A
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 V751A were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 V751A
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 V751A were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 V751A
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 V751A were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 V751A
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 V751A were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R809Q
|
Advanced Solid Tumor
|
predicted - sensitive
|
Fexagratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R809Q were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R809Q
|
Advanced Solid Tumor
|
predicted - sensitive
|
Infigratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R809Q were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R809Q
|
Advanced Solid Tumor
|
predicted - sensitive
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R809Q were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R809Q
|
Advanced Solid Tumor
|
predicted - sensitive
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R809Q were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R809Q
|
Advanced Solid Tumor
|
predicted - sensitive
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R809Q were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 R809Q
|
Advanced Solid Tumor
|
predicted - sensitive
|
E7090
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 R809Q were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467).
|
34272467
|
|
FGFR1 V561F
|
Advanced Solid Tumor
|
resistant
|
Infigratinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Truseltiq (infigratinib) treatment failed to inhibit cell growth, Fgfr1 phosphorylation, and downstream pathway activation in cells expressing FGFR1 V561F in culture and failed to inhibit tumor growth in a cell line xenograft model with a tumor growth inhibition of 2.4% (PMID: 34114373).
|
34114373
|
|
FGFR1 V561F
|
Advanced Solid Tumor
|
predicted - resistant
|
Erdafitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, cells expressing FGFR1 V561F demonstrated insensitivity to Balversa (erdafitinib) in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 V561F
|
Advanced Solid Tumor
|
predicted - resistant
|
Futibatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, treatment with Lytgobi (futibatinib) failed to inhibit cell growth and Fgfr1 downstream signaling in cells expressing FGFR1 V561F in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 V561F
|
Advanced Solid Tumor
|
predicted - resistant
|
Pemigatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, treatment with Pemazyre (pemigatinib) failed to inhibit cell growth and Fgfr1 downstream signaling in cells expressing FGFR1 V561F in culture (PMID: 34114373).
|
34114373
|
|
FGFR1 V561F
|
Advanced Solid Tumor
|
sensitive
|
Olverembatinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Olverembatinib (HQP1351) treatment inhibited cell growth, Fgfr1 phosphorylation, and downstream pathway activation and induced cell cycle arrest and apoptosis in cells expressing FGFR1 V561F in culture and inhibited tumor growth in cell line xenograft models, with a tumor growth inhibition of 73.4% (PMID: 34114373).
|
34114373
|
|
FGFR1 M563T
|
intrahepatic cholangiocarcinoma
|
predicted - sensitive
|
Futibatinib
|
Case Reports/Case Series |
Actionable |
In a Phase I trial, Lytgobi (futibatinib) treatment led to an overall objective response rate of 15.8% (3/19, 3 partial responses) and a disease control rate of 47.4% (9/19), with stable disease in 6, in patients with urothelial cancer harboring an FGFR3 mutation or FGFR1 mutation, including a partial response with a progression-free survival of 6.8 mo and a duration of response of 5.6 mo in a urothelial cancer patient harboring FGFR1 M563T and amplifications in FGF3 and FGF19 (PMID: 34551969; NCT02052778).
|
34551969
|
|
FGFR1 M532T
|
transitional cell carcinoma
|
predicted - sensitive
|
Pembrolizumab + Pemigatinib
|
Case Reports/Case Series |
Actionable |
In a Phase I trial (FIGHT-101), treatment with the combination of Pemazyre (pemigatinib) and Keytruda (pembrolizumab) demonstrated safety in patients with advanced solid tumors and resulted in an objective response rate of 26.9% (7/26, all partial responses), including a partial response with a duration of response of 6.5 months in a patient with urothelial cancer harboring FGFR1 M532T (PMID: 38986210; NCT02393248).
|
38986210
|
